CONFIDENTIAL & PROPRIETARY / TRADE SECRET
NOT SUBJECT TO DISCLOSURE UNDER THE FREEDOM OF INFORMATION ACT OR VERMONT PUBLIC RECORDS LAW

VIA E-MAIL

January 11, 2023

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404

Office of the Vermont Attorney General
Attention: Attorney General, Susanne R. Young
109 State Street
Montpelier, VT 05609
AGO.highcostprescriptiondrugs@vermont.gov

Dear Attorney General Donovan:

This letter provides notice, as required by Section 4637(b) of Vermont Act 193, as codified at 18 VT. Stat. Ann. § 4637 ("Act 193") that Gilead Sciences, Inc. ("Gilead") released the following new prescription drugs to market at a wholesale acquisition cost above that of a specialty drug under the Medicare Part D program:

- SUNLENCA® (lenacapvir) sterile solution for injection, 309 mg/mL, 1.5 mL/vial, 2 vial kit (NDC 61958-3002-01);
- SUNLENCA® (lenacapvir) tablet, 300 mg, 4 count, blister pack (NDC 61958-3001-01); and
- SUNLENCA® (lenacapvir) tablet, 300 mg, 5 count, blister pack (NDC 61958-3001-02).

The WAC exceeding the Medicare Part D program price reflects SUNLENCA's clinical efficacy, safety profile, as well as access and market conditions.

Section 4637 of Act 193 does not currently define "release of the drug in the commercial market." Further, Gilead is not aware of any guidance issued by the Office of the Attorney General (the "Office") or any Vermont regulation that defines "release of the drug in the commercial market" for purposes of Section 4637. Gilead interprets "release of the drug in the commercial market" to mean when Gilead makes a drug available for order.

We understand that, pursuant to Section 4637(e) of Act 193, the Office will publish information reported pursuant to Section 4637 on its website. Accordingly, we have attached a single-page version of this notice the Office can publish on its website while preserving the signatory's right

to privacy, consistent with Section 317(c)(10) of Title 1 of the Vermont Statutes Annotated. We ask that the Office only publish the single-page version of this notice on its website, pursuant to Section 4637(e) of Act 193.

Sincerely,



Alesia Wilbekin
Executive Director, Managed Markets Strategy and Operations
Gilead Sciences, Inc.

Notice of New Drug Pursuant to Section 4637 of Vermont Act 193

This letter provides notice, as required by Section 4637(b) of Vermont Act 193, as codified at 18 VT. Stat. Ann. § 4637, that Gilead Sciences, Inc. released the following new prescription drugs to market on January 9, 2023 at a wholesale acquisition cost above that of a specialty drug under the Medicare Part D program:

- SUNLENCA® (lenacapvir) sterile solution for injection, 309 mg/mL, 1.5 mL/vial, 2 vial kit (NDC 61958-3002-01);
- SUNLENCA® (lenacapvir) tablet, 300 mg, 4 count, blister pack (NDC 61958-3001-01); and
- SUNLENCA® (lenacapvir) tablet, 300 mg, 5 count, blister pack (NDC 61958-3001-02).

The WAC exceeding the Medicare Part D program price reflects SUNLENCA's clinical efficacy, safety profile, as well as access and market conditions.